Pleural Diseases: Surgery For Malignant Pleural Mesothelioma-Egyptian View

Ribak J, Lilis R, Suzuki Y, et al. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death. Br J Ind Med 2008; 45: 182–187.

Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260–271.

Armstrong BK, Musk AW, Baker JE, et al. Epidemiology of malignant mesothelioma in Western Australia. Med J Aust 1984; 141: 86–88

Gennaro V, Ceppi M, Boffetta P, et al. Pleural mesothelioma and asbestos exposure among Italian oil refinery workers. Scand J Work Environ Health 1994; 20: 213–215.

Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011;6(8):1304‐1312.

Scherpereel, A., Astoul, P., Baas, P. et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010; 35: 479–495

Van Schil, P.E., Opitz, I., Weder, W. et al. Multimodal management of malignant pleural mesothelioma: where are we today? Eur Respir J. 2014; 44: 754–764.

Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One. 2014;9(1):e87060.

Bilancia R, Nardini M, Waller DA. Extended pleurectomy decortication: the current role. Transl Lung Cancer Res 2018;7(5):556-561.

Rintoul RC, Ritchie AJ, Edwards JG, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118‐1127.

Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition). Spilker B (Ed.). Lippincott-Raven Publishers, Philadelphia, PA, USA, 191–201 (1996)

Soysal O, Karaoglanoglu N, Demiracan S. et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg. 1997; 11: 210-213

Wanebo H.J, Martini N, Melamed M.R. et al. Pleural mesothelioma. Cancer. 1976; 38: 2481-2488

Friedberg J.S, Mick R, Culligan M et al. Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg. 2011; 91: 1738-1745

Kostron A, Friess M, Inci I. et al. Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients. Interact Cardiovasc Thoracic Surg. 2017; 24: 740-746

Anegg U, Lindenmann J, Matzi V, et al. Efficiency of fleece-bound sealing (TachoSil) of air leaks in lung surgery: a prospective randomised trial. Eur J Cardiothorac Surg 2007;31:198-202.

Elsayed H, McShane J, Shackcloth M. Air leaks following pulmonary resection for lung cancer: is it a patient or surgeon related problem?. Ann R Coll Surg Engl. 2012;94(6):422-427.

Sharkey AJ, Bilancia R, Tenconi S, Nakas A, Waller DA. The management of the diaphragm during radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016 Aug; 50(2):311-6.

Al-Nouri O., Hartman B., Freedman R., Thomas C., Esposito T. Diaphragmatic rupture: is management with biological mesh feasible. Int. J. Surg. Case Rep. 2012;3:349–353.

Chilintseva N., Brigand C., Meyer C., Rohr S. Laparoscopic prosthetic hiatal reinforcement for large hiatal hernia repair. J. Visc. Surg. 2012;149:e215–e220.

Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763-772.

Cho BC, Feld R, Leighl N, et al. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma. J Thorac Oncol 2014;9:397-402

de Perrot M, Feld R, Leighl NB, et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2016;151:468-73.

Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620-626.e6263.

Eelco de Bree, Serge van Ruth, Paul Baas, et al. Cytoreductive Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy in Patients with Malignant Pleural Mesothelioma or Pleural Metastases of Thymoma. Chest. 2002 Feb;121(2):480-7.

Mahesh D. Patel, Dileep Damodaran, Ashvin Rangole, et al. Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies-Experience from Indian Centers. Indian J Surg Oncol. 2019 Feb;10(Suppl 1):91-98.

Michael Ried, Tobias Potzger, Nico Braune, et al. Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy Perfusion for Malignant Pleural Tumours: Perioperative Management and Clinical Experience. Eur J Cardiothorac Surg. 2013 Apr;43(4):801-7.

Till Markowiak, Nadine Kerner, Reiner Neu et al. Adequate Nephroprotection Reduces Renal Complications After Hyperthermic Intrathoracic Chemotherapy. J Surg Oncol. 2019 Dec;120(7):1220-1226.

Y Matsuzaki, K Shibata, M Yoshioka, et al. Intrapleural Perfusion Hyperthermo-Chemotherapy for Malignant Pleural Dissemination and Effusion. Ann Thorac Surg. 1995 Jan;59(1):127-31.

Marcello Migliore, Damiano Calvo, Alessandra Criscione, et al. Cytoreductive Surgery and Hyperthermic Intrapleural Chemotherapy for Malignant Pleural Diseases: Preliminary Experience. Future Oncol. 2015;11(2 Suppl):47-52.

Marcello Carlo Ambrogi, Pietro Bertoglio, Vittorio Aprile, et al. Diaphragm and Lung-Preserving Surgery With Hyperthermic Chemotherapy for Malignant Pleural Mesothelioma: A 10-year Experience. J Thorac Cardiovasc Surg. 2018 Apr;155(4):1857-1866.e2.

Hua Zhou, Wei Wu, Xiaoping Tang, at al. Effect of Hyperthermic Intrathoracic Chemotherapy (HITHOC) on the Malignant Pleural Effusion: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2017 Jan;96(1):e5532.

Politi L, Borzellino G. Second surgery for recurrence of malignant pleural mesothelioma after extrapleural pneumonectomy. Ann Thorac Surg. 2010;89(1):207‐210.

Burt, B.M., Ali, S.O., DaSilva, M.C. et al. Clinical indications and results after chest wall resection for recurrent mesothelioma. J Thorac Cardiovasc Surg. 2013; 146: 1373–1379

Kostron, A., Friess, M., Crameri, O. et al. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016; 49: 1516–1523

Schwartz RM, Lieberman-Cribbin W, Wolf A, Flores RM, Taioli E. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. BMC Cancer. 2018;18(1):1188.

Lim E. 195 A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study. Lung Cancer 2016;91:S71 10.1016/S0169-5002(16)30212-4

Raskin J, Surmont V, Cornelissen R, Baas P, van Schil PEY, van Meerbeeck JP. A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205). Transl Lung Cancer Res. 2018;7(5):593-598.

Matthews C, Freeman C, Sharples LD, et al. MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial. BMJ Open Respir Res. 2019;6(1):e000368.